Research Article
Genome-Wide Screening of Cytogenetic Abnormalities in Multiple Myeloma Patients Using Array-CGH Technique: A Czech Multicenter Experience
Table 1
Patients’ baseline characteristics.
| | Sex | | | Males | 41 | | Females | 50 | | Age median | | | (at the time of therapy, years); range | 69 (38–87) | | Follow-up median | | | (from therapy, months); range | 37.8 (1.7–269.8) | | Durie-Salmon stage (from therapy) | | | I | 9 (9.9%) | | II | 11 (12.1%) | | III | 71 (78.0%) | | Stages A-B (from therapy) | | | A | 69 (75.8%) | | B | 22 (24.2%) | | ISS stage (from therapy) | | | 1 | 22 (24.2%) | | 2 | 25 (27.5%) | | 3 | 44 (48.4%) | | Ig isotype | | | IgG | 58 (63.7%) | | IgA | 15 (16.5%) | | IgD | 4 (4.4%) | | IgM | 1 (1.1%) | | LC only | 13 (14.3%) | | Light chains | | | Kappa | 53 (58.2%) | | Lambda | 38 (41.8%) | | Number of previous treatment lines | | | None (first line treatment) | 46 (50.6%) | | Two | 20 (22.0%) | | More (>2) | 25 (27.4%) | | Biochemical parameter (median; min–max) | | | Haemoglobin (g/L) | 103.50 (66–144) | | Thrombocytes (count ×109) | 197.50 (27–416) | | Calcium (mmol/L) | 2.32 (1.47–3.64) | | Albumin (g/L) | 38.95 (21.1–54.1) | | Creatinine (umol/L) | 113.00 (54–1136) | | β2-Microglobulin (mg/L) | 5.18 (1.8–42.16) | | Lactate dehydrogenase (ukat/L) | 3.80 (1.52–22.92) | | C-reactive protein (mg/L) | 4.20 (0–174) | | Plasma cell infiltration of bone marrow (%) | 39.4 (0.80–94.60) |
|
|
